OVARIAN CANCER

Common complications of ovarian cancer tumor rupture, hemorrhage, secondary infection, anemia, cancer of the intestine cancer and intestinal infarction colic.

(1), ovarian cancer-chemotherapy drug commonly used drug <BR> melphalan (PAM) 0.2 ^ / ㎏ d, oral, 4 ~ for a course on the 5th, rest four to six weeks after duplication. Thiotepa (161-169) 10 ^ / times, intramuscular or intravenous injection, used five times, every other day to once a total of 300 ~ 500 days for an induction course. 6 to 8 weeks under the condition repeat. Cyclophosphamide (CTX) 50 ~ 100 ^ / day, oral, 7 ~ 10 Tianyi treatment, two weeks after duplication. Or 400 ^ / day, intravenous, oral to four days. Adriamycin (ADM) 50 ~ 70 ^ / ㎡, intravenous injection. Every three weeks.
(2), and malignant ovarian tumor joint chemical treatment of ovarian cancer chemotherapy are better response. In recent years the chemical treatment of tumors faster progress in the treatment of ovarian cancer Habitat has an important place to improve the treatment of ovarian cancer play a positive role as a surgical adjuvant therapy, commonly used in the preoperative, intraoperative and postoperative, but often require a longer period of intermittent medication, and the human body toxicity also sometimes larger. In most cases, it is difficult to ovarian cancer surgery primary tumor and metastasis consider chemical treatment based treatment.

Most of the malignant ovarian tumors, radiation therapy for various effects are poor. Therefore, in the treatment of malignant ovarian tumor was not first consider radiotherapy. After laparotomy confirmed to be malignant ovarian tumor resection not all, in vitro viable X-ray irradiation. But many of ascites are not OK radiotherapy; The abdominal tumor metastasis to the effect of not limited to those within the pelvic cavity. X-ray irradiation is also used in vitro malignant ovarian tumor before and after surgery. Preoperative radiotherapy for patients with radiation therapy after the word four to six weeks should surgery again night, while radiation caused by adhesions, surgery often caused difficulties. Surgery will be in regular radiation treatment after two weeks before and after the start, such as whole body ill patients should first correct.
(1), abdominal irradiation radiation field including full pots of abdominal viscera, or by Ono divided into two to four vertical irradiation of Ono, tumor dose of 25 Gy ~ / 6 to 8 weeks. General liver, kidney tolerance were 30 Gy and 18 Gy, such as the super-dose, should shielding protection. Whole abdominal irradiation after Ono, the largest general tolerance of 30 Gy / 6 to 7 weeks. This dose is not LD50 of ovarian cancer, while Ono irradiation reaction, difficult patient tolerance. Delcios in 1963, a fully mobile strip abdominal irradiation in the treatment of ovarian cancer. Each abdominal irradiation of 10 cm, radiation field from the upward movement in the entire basin to include abdominal, each irradiation in 12 days. Tumor radiation dose of 26 to 28 Gy. The biological effects of radiation and improve the patient's response to radiotherapy.
(2), pelvic tumor irradiation dose of 40 to 60 Gy, 6 to 8 weeks to complete.
(3), plus whole abdominal pelvic irradiation Ono whole abdominal irradiation may be, or transfer surgery strip irradiation dose with the former. Pelvic organ tolerance, to improve efficacy, and pelvic irradiation dose of 20 to 30 Gy, ovarian cancer is the commonly used method.
(4), abdominal radionuclide therapy for patients early preventive treatment, and only a small residual tumor after treatment. Surgery not cut net of malignant ovarian tumor metastases can be injected with the radioactive colloid 98 or 32 P, or diluted with saline injected into the abdominal cavity to prevent cancer formation of ascites, malignant ovarian cancer has been with ascites, the catheter may produce ascites part, to be injected colloidal gold 98 or 32 P . It should be noted 98 of the radioactive colloid and 32 P for intraperitoneal injection, also caused radioactive hepatitis possible, it should be repeated in application check liver function for timely processing.

1. Bilateral abdominal tumor malignant ovarian tumor growth, both accounting for 75%, and bilateral benign ovarian tumor was only 15%.

2. Mass fixed One of the characteristics of ovarian cancer.

3. Although ascites benign ovarian tumors such as fibroids or papillary also cystadenoma with ascites, malignant ovarian tumor with ascites more, and because of the cancer cell wall or piercing has been transferred to peritoneal (Head seized observation or examination), a sustained bloody ascites.

4. Cachexia course of a long delay, due to long-term consumption, loss of appetite and weight loss sexual performance, fatigue, malaise and cachexia symptoms.

A scholar from the Netherlands led multinational collaborative research suggest that the early epithelial ovarian cancer surgical staging, can predict whether the patients have residual ovarian cancer and the need for postoperative adjuvant chemotherapy.

Abdominal mass
Medium large following abdominal tumor, without complications or malignant, its greatest feature is movable, can often move from abdominal pelvic push.
Mass General of tenderness, but in case of complications or malignant transformation, tumor itself is not only tenderness, and even stimulate peritoneal symptoms.

Levy ascites
There often ascites tumor characteristics, such as benign ovarian cyst and fibroid may produce ascites papillary cystadenoma. Endocrine symptoms such as hair, voice role the extra change, as the masculine clitoral hypertrophy cyst.

Cachexia
It is characterized by extreme abdominal swelling, significant weight loss, painful facial expressions and serious diseases.

In recent decades, the treatment of gynecologic cancer progress has been made, but only the ovarian cancer there is no significant improvement. The incidence of ovarian cancer Habitat Gynecologic Oncology third, but it was the first fatality rate. Its cause high mortality due to the growth of ovarian cancer site concealment, not be seen directly, patients still in the early stages of the lack of simple and practical method of diagnosis. Most (about 70%) have been newly diagnosed patients with peritoneal metastasis pots. Currently taken by surgery, radiotherapy, chemotherapy and immunotherapy for the treatment of Chinese medicine integrated with the right therapy, in the treatment of advanced worse still, it is difficult to avoid recurrence. But by early diagnosis and treatment of patients with ovarian cancer prognosis is quite different. Case in epithelial ovarian cancer, according to statistics, the five-year survival rate, 80% for stage I, 40% for Stage II; While Ⅲ period just below 5%. Visibility early detection, early diagnosis and treatment of patients with ovarian cancer is a lifetime event.

Ovarian cancer early detection, early treatment, the greater the chance of cure. But ovarian cancer early detection more difficult. Usually, women with ovarian cancer no symptoms or mild discomfort, only to the late period before a noticeable symptoms. Scientists are studying the symptoms, identify methods of ovarian cancer. They found blood in the CA-125, a tumor marker in women with ovarian cancer was significantly increased; Ultrasound can also help early detection of diseases.
The census is a large-scale tumors, including prostate, lung, colorectal and ovarian cancer, the evaluation of tumor markers in the blood of the level of CA-125 and transvaginal ultrasound examination in the early diagnosis of ovarian cancer value.

Researchers in the United States on the 10th reported that they found a blood-screening early detection of ovarian cancer and new ways to its accuracy rate of 95%.
In Las Vegas, Nevada Cancer Institute researchers published this week in the "Journal of the National Academy of Sciences," the report said, they discovered in experiments in the blood of ovarian cancer patients are four species of the overall level of the protein showed a similar pattern. Four proteins leptin, Lactagogue hormone, osteopontin and insulin-like growth factor.